Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLANETTE
2024-515102-12-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of ceralasertib in cancer (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Investigator assessed objective response rate (ORR) in Module 1 - Cohort A and Composite response rate in Module 1 - Cohort B. Started Aug 2024; status: completed.
02
Drugs
ceralasertib
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-515102-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515102-12-00.